(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2007 (05.07.2007)

PCT

(10) International Publication Number
WO 2007/075605 A3

(51) International Patent Classification:
A61K 31/19 (2006.01) *A61P 35/00* (2006.01)
A61P 37/08 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:
PCT/US2006/048303

(22) International Filing Date:
19 December 2006 (19.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/752,253 19 December 2005 (19.12.2005) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; Dept. 377/AP6A-1, 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **THOMAS, Debra, L.** [US/US]; 1078 Trentwood Road, Columbus, Ohio 43221 (US). **MUKERJI, Pradip** [US/US]; 1069 Arcaro Drive, Columbus, Ohio 43230 (US).

(74) Agents: **WINTER, William, J.** et al.; 108140 DS1, 625 Cleveland Avenue, Columbus, OH 43215 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
26 June 2008

(54) Title: USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE TO MODULATE THE IMBALANCE IN TYPE AND TYPE 2 CYTOKINE PRODUCTION



	IFN: IL-4	IFN: IL-5	IFN: IL-13	IFN: IL-10
0 mM HMB	42.71	11.1	5.59	14.23
1 mM HMB	42.55	11.61	5.81	14.49
5 mM HMB	46.47	12.51	5.99	14.61
10 mM HMB	50.16	14.04	6.47	18.16

(57) Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type (1) and type (2) cytokine production, wherein the method comprises administering to the individual an amount of &bgr; -hydroxy- &bgr; -me thylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type (1) to type (2) cytokines, including an increase in the ratio of type (1) to type (2) cytokines without a corresponding increase in type (2) cytokine levels. Also disclosed are methods of using HMB to treat asthma, allergies and cancer. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type (1) cytokines without a corresponding increase in type (2) cytokines.

WO 2007/075605 A3